R1 RCM — Q3 2020 Earnings Presentation
13 slides from R1 RCM's earnings presentation, Nov 3, 2020
Slide 1: Third Quarter 2020 Results Conference Call
Exhibit 99.2 Third Quarter 2020 Results Conference Call November 3, 2020
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not pa
Slide 3: Q3 Financial Highlights and 2020 Outlook
Q3 Financial Highlights and 2020 Outlook ThirdThird Quarter Quarter 2020 2020 Financial Financial Highlights Results ▪ Revenue of $307.2 million, up $6.0 million and 2.0% compared to the same period last year ▪ GAAP net income of $5.2 million, compared to GAAP net income of $9.2 million in the same
Slide 4: Commercial Update
Commercial Update NewNew Operating Operating Partner Partner Agreement Agreement with with LifePoint LifePoint Health Health ▪ $2.8 billion in annual net patient revenue (NPR) under management ▪ 10-year term ▪ Onboarding expected to commence in January 2021 ▪ Economics expected to be in line with Op
Slide 5: Tech Investments and Extending our Competitive Positioning
Tech Investments and Extending our Competitive Positioning ▪ Technology is an increasingly important deciding factor in the customer selection process ▪ Current priority areas: 1.PatientPatient Experience Experience Platform Platform (PX) (PX) ▪ Patient engagement is high with net promoter score ≥75
Slide 6: Deployment and M&A Update
Deployment and M&A Update Deployment Activity Penn State Health ▪ Initiated onboarding activities in May, on track to be completed by Q1 2021 ▪ Both teams have collaborated extremely well under a virtual model, early results are very positive Rush University System for Health (RUSH) ▪ Continues to p
Slide 7: COVID-19 Update and Volume Trends
COVID-19 Update and Volume Trends Health and Safety of Workforce Remains Top Priority ▪ Vast majority of employees continue to work from home ▪ Productivity, engagement and retention remain at satisfactory levels Operating Environment Remains Dynamic ▪ Patient volumes have trended at 90-95% of pre-C
Slide 8: 3Q'20 non-GAAP Results – Q/Q and Y/Y Comparison
3Q’20 non-GAAP Results – Q/Q and Y/Y Comparison ($ in millions) 3Q'20 2Q'20 3Q'19 Key change driver(s) • Q/Q: Impact of Covid pressure on patient volumes from March-April lockdown Revenue $307.2 $314.7 $301.2 • Y/Y: Contribution from new customers and acquisitions, offset by Covid-related volume dec
Slide 9: Additional Commentary
Additional Commentary Net debt1 of $453.7 million as of 9/30/20, including restricted cash ▪ Up sequentially due to working capital changes, M&A related spend and capital expenditures Sufficient liquidity to withstand a wide range of scenarios ▪ Cash (after giving effect to ~$130 million in proceeds
Slide 10: Appendix
Appendix 10
Slide 11: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance mea
Slide 12: Reconciliation of GAAP to non-GAAP Financials
Reconciliation of GAAP to non-GAAP Financials $ in millions Reconciliation of GAAP Net Income to non-GAAP Adjusted EBITDA Three Months Ended Three Months Ended September 30, June 30, 2020 2019 2020 Net income $ 5.2 $ 9.2 $ 15.1 Net interest expense 4.4 5.0 4.8 Income tax provision 1.0 9.4 5.2 Deprec
Slide 13: Reconciliation of GAAP to non-GAAP Financials
Reconciliation of GAAP to non-GAAP Financials $ in millions Reconciliation of GAAP Operating Income Guidance to Non-GAAP Adjusted EBITDA Guidance 2020 GAAP Operating Income Guidance $90-110 Plus: Depreciation and amortization expense $65-75 Share-based compensation expense $20-25 Strategic initiativ